Pharmacyte Biotech Inc (OTCMKTS:PMCB) saw a sharp drop last week after the Company announced it is contracting with Translational Drug Development (TD2) in Scottsdale, Arizona, to conduct an additional preclinical study related to determining the effectiveness of its Cell-in-a-Box® live-cell encapsulation technology together with the anticancer drug ifosfamide in slowing the accumulation of fluid in the abdomen that accompanies the growth of pancreatic and other abdominal cancerous tumors. This fluid is commonly known as “malignant ascites fluid.”
PMCB continues to command a massive following that supports the stock and for good reason; when PMCB heats up it goes big running from a dime to over $0.60 a share this time last year.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon their unique, proprietary and patented cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.
The live-cell encapsulation technology employed by Pharmacyte Biotech is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed.
Dr.Mark Rabe, chairman of the advisory board of Pharmacyte Biotech subsidiary, Medical Marijuana Sciences (MMS) summed it up perfectly when he said ”The live cell encapsulation platform employed by Nuvilex is a unique patented technology on which treatments can be developed for deadly and debilitating diseases such as cancer and diabetes. The technology has shown to be successful in the treatment of pancreatic cancer in initial clinical trials using the conventional chemotherapy drug ifosphamide. ”
To get a sense of just how valuable this technology could be, consider a recent report published by U.S. based market research company, Transparency Market Research “ the global diabetes devices and drugs market was valued at USD 54.04 billion in 2012 and is estimated to reach a market worth of USD 83.0 billion in 2019 growing at a CAGR of 5.9% from 2013 to 2019.
Many investors in the Company view Pharmacyte Biotech Cell-in-a-Box® cell encapsulation technology as THE future of diabetes treatment and suggest the Company is a prime buy out candidate from a major such as Bayer who may be closely watching PMCB.
PMCB has benefited from the pot connection; the sector is heating up again big time with a recent report from MMJ Business Daily suggesting that 2015 is expected not only to see more investment dollars flow into the market but it could even outpace the growth rate seen in 2014. States like Nevada, Illinois, Massachusetts, Oregon, and Alaska have all been identified as industry drivers this year. Furthermore, the rise in “big money” from some major investment funds has just started to hit the sector.
To Find out the inside Scoop on PMCB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Pharmacyte Biotech subsidiary, Medical Marijuana Sciences, Inc., is exploring the benefits of using the Cell-in-a-Box(TM) technology in optimizing the anticancer effectiveness of cannabinoids while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.
PMCB landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe who was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS).
In fact Pharmacyte Biotech has been very successful in attracting top talent to the Company including their COO Dr. Crabtree who used to work at Bristol Meyers and successfully managed the project that achieved FDA approval for Taxol. Another huge asset is their Chief Scientific Officer ; Dr. Robert F. Ryan an expert in helping small companies in bringing their products to market through the rigorous FDA approval process.
We have a Monster Pick Coming. Subscribe Right Now!
Pharmacyte Biotech has made some huge steps recently towards accelerated FDA approval for its pancreatic cancer treatment using Phase 2b data that outperformed Eli Lilly’s Gemzar in prior trials; according to available information the Cell-In-The-Box technology beats the current Gold Standard on The market, and we are talking about a market worth billions. Pharmacyte Biotech has made some huge steps recently towards accelerated FDA approval for its pancreatic cancer treatment using Phase 2b data that outperformed Eli Lilly’s Gemzar in prior trials. The New Year promises to be big for Pharmacyte Biotech. We will be updating on PMCB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with PMCB.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in PMCB either long or short and we have not been compensated for this article.